Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Investor Presentation Corporate Fact Sheet

Latest News

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026

November 2, 2026

IMUNON Announces Strategic Sale of ThermoDox®

October 21, 2026

IMUNON to Participate in Upcoming Investor Conferences

October 8, 2026

Financial Events

Presentation at the 2026 ThinkEquity Conference

October 15, 2026 at 1:30 PM EDT

Oncology Panel Presenation at the Maxim Growth Summit 2026

October 14, 2026 at 9:00 AM EDT